Bringing a therapy to market is a defining milestone, yet it is rarely the point at which uptake meaningfully accelerates. Even with increasingly sophisticated launch frameworks, underperformance remains common – particularly in rare disease – shaped by complex care ecosystems and small, heterogeneous patient populations.^1,2 In practice, launch often reaches a mere fraction of eligible patients, with real growth unfolding in the months that follow.³

In rare and specialty settings, early trajectory is less determined by large post-approval evidence programs and more by how effectively patients are identified, how healthcare professionals (HCPs) integrate the therapy into practice and how care pathways reorganize around a new standard of care.^1,3,4

This article explores six interdependent drivers of post-launch acceleration: activating patients and HCPs, growing through patient waves, evolving engagement, strengthening ecosystem coordination, adapting execution and preserving brand energy beyond launch.

Pillar 1. Acceleration at the patient-HCP intersection

Uptake is shaped less by knowing a therapy is available and more by whether patients recognize themselves in the disease narrative, understand the relevance of a new option and feel sufficiently informed to initiate discussions with their care team. At the same time, HCPs must feel confident about identifying appropriate patients and integrating treatment into established workflows.¹

The point at which informed patients and prepared HCPs meet – the practical “collision point” in the consultation room – is often where acceleration occurs. When both sides are aligned in awareness and confidence, momentum builds more naturally.

Pillar 2. Recognizing that growth unfolds in waves

Early adoption is typically concentrated within a relatively small initial cohort, with subsequent growth driven by sustained engagement rather than by the launch moment itself.¹ This dynamic is better understood through patient waves than static segmentation.

Therapy-naïve patients may surface as disease awareness improves or diagnostic confidence increases. Switch patients, already embedded in established care pathways, require a clear articulation of value within existing treatment paradigms – particularly from the treating specialist’s perspective. Over time, additional waves often emerge through referral dynamics and patients previously lost to follow-up.

These patients represent a meaningful but frequently underestimated opportunity. Having disengaged from specialist care due to historical treatment limitations or fragmented journeys, they are among the most challenging to identify and re-engage. Reaching this group typically depends less on traditional promotion and more on sustained, trust-based engagement through channels and communities patients already recognise.^5,6

Pillar 3. Sustaining activation through evolving engagement

Sustaining activation across waves requires narratives that evolve as familiarity increases. As stakeholders move beyond initial awareness, their focus shifts from understanding the therapy’s rationale to determining how and when to use it in concrete clinical situations. Engagement must therefore keep pace with the increasing specificity of real-world questions.

Early interactions typically center on disease burden and clinical rationale. As experience builds, discussions move toward patient selection, initiation logistics and management considerations informed by early use. Engagement plans should reflect this shift by sequencing content deliberately and aligning dialogue with the stakeholder’s stage of familiarity.

Supporting this progression also requires internal readiness. Field teams need structured updates, scenario-based preparation and access to timely medical insights so that conversations remain grounded in practice rather than theory.⁷

Pillar 4. Strengthening patient capture through ecosystem coordination

In rare and ultra-rare disease, growth is less about scale and more about capture and continuity. Even motivated patients may be identified late, referred inconsistently or lost between diagnosis, specialist assessment and treatment initiation.^3,6

Many eligible patients only surface after approval, as diagnostic confidence improves and pathways stabilize around a new standard of care. Uptake therefore depends on how effectively the ecosystem reduces friction and prevents leakage across the journey.

Patient advocacy groups and rare disease communities play a critical role, though their impact varies with community maturity. In more established ecosystems, advocacy organizations can accelerate case finding, disseminate trusted education and reconnect patients to specialist care. In more fragmented settings, foundational work is often required before pathways function reliably.^3,6

For companies, this shifts the focus from driving volume to strengthening coordination. Improving referral clarity, aligning narratives across patients, advocates and HCPs and supporting pathway coherence can materially improve patient capture over time. In ultra-rare settings, even modest reductions in leakage can meaningfully influence overall uptake.

In this context, post-launch evidence tends to reinforce confidence rather than drive growth. Targeted insights from early clinical experiences or medical exchanges can help stabilize pathways and sustain trust without relying on resource-intensive programs that are often impractical in small populations.⁶

Pillar 5. Adapting execution as learning accumulates

As real-world experience accumulates, internal understanding of the therapy deepens. Early insights reveal where assumptions hold, where friction persists and which elements of the launch approach require recalibration.

Sustained success depends on maintaining alignment as learning evolves. Teams that can interpret early experience and apply adjustments consistently across medical, commercial and field functions are better positioned to refine execution without introducing mixed signals into a small and closely connected community.^1,2,5

Pillar 6. Preserving brand energy beyond launch

An often underaddressed challenge is preserving brand energy beyond the initial launch phase. While significant attention is placed on approval and launch readiness, comparatively less focus is devoted to sustaining structured engagement in the months that follow. Research shows that brands lose traction not because strategy is flawed, but because execution and narratives fail to evolve in a coordinated way as familiarity increases.^5,8

In rare disease, interactions between HCPs, patients and advocacy groups are highly visible and repeated, so inconsistency is quickly noticed. Continued alignment, refreshed engagement and confident field enablement should therefore be considered part of responsible launch design.

Designing post-launch success from day one

In rare and transformative medicine, post-launch carries particular weight in the first year. Momentum builds where informed patients and confident HCPs connect within a coordinated ecosystem, and where organizations adapt without losing clarity of direction.

Designing for this phase means activating patient and professional audiences, strengthening referral pathways, adapting as experience builds and preserving brand energy so momentum continues rather than plateaus.

At Cognite, we draw on more than a decade of experience supporting pharmaceutical teams in rare and specialty settings. We work alongside organizations to help translate scientific innovation into meaningful engagement across patients and HCPs, supporting the shift from approval to sustained real-world impact.

If you are preparing for post-launch activities or would simply like to have a conversation, feel free to contact Stephen Piotrowski, our US Business Lead, at stephen.piotrowski@cognite.co, or connect with any member of the Cognite team.

References:

1. IQVIA. Modern launch: the new playbook for brand commercialization in pharma. Available at https://www.iqvia.com/locations/united-states/blogs/2025/10/modern-launch-the-new-playbook-for-brand-commercialization-in-pharma [accessed March 2026].
2. EY. Tech and people balanced for a successful launch. Available at https://www.ey.com/en_gl/insights/life-sciences/how-biopharma-can-get-the-right-mix-of-people-and-tech-for-launch-success [accessed March 2026].
3. IQVIA. From Orphan to Opportunity: Mastering Rare Disease Launch Excellence. IQVIA White Paper. Available at: iqvia.com/-/media/iqvia/pdfs/library/white-papers/from-orphan-to-opportunity-mastering-rare-disease-launch-excellence.pdf [accessed March 2026].
4. McKinsey & Company. Beyond the storm: launch excellence in the new normal. Available at https://www.mckinsey.com/~/media/mckinsey/industries/healthcare%20systems %20and%20services/our%20insights/the%20secret%20of%20successful%20drug %20launches/beyond_the_storm_launch_excellence_in_the_new_normal.ashx [accessed March 2026].
5. Bastion Brands. Launching and growing a pharma product in disrupted times. Available at https://bastionbrands.com.au/launching-and-growing-a-pharma-product-in-disrupted-times/ [accessed March 2026].
6. Dirk Moritz. A Framework for Successful Launching & Commercializing Rare Disease Product. BlueMatter Consulting. https://bluematterconsulting.com/insights/blog/rare-disease-product-launch-commercialization/ [accessed March 2026].
7. Wall Street Journal. Rx for growth: how drugmakers can optimize post-launch strategy. Available at https://deloitte.wsj.com/cmo/rx-for-growth-how-drugmakers-can-optimize-post-launch-strategy-b5b71aed [accessed March 2026].
8. Uptake Strategies. Why Launch Excellence Still Sets Pharma Market Leaders Apart. Available at: https://uptakestrategies.com/why-launch-excellence-still-sets-pharma-market-leaders-apart/#:~:text=Pharma%20leaders%20stand%20out%20by%20treating %20launch%20excellence,patient%20focus%20and%20strong%20team %20alignment.%20Learn%20more [accessed March 2026].